Specialty medications are often expensive and need careful handling, close monitoring, and special approval from insurance companies and pharmacy managers. These drugs make up about half of all prescription spending in the U.S. and almost three-quarters of the drugs being developed now, according to the FDA. Even though these medicines are important, doctors and clinics often face delays because the approval process is complicated.
Several factors make it hard to get specialty drugs:
Usually, clinical staff or administrative teams do these steps. This raises labor costs and increases the chance of mistakes.
Multi-agent AI means that many AI units or “agents” work together to do complex jobs. Unlike regular AI that only does one task, these agents can plan, act, think about how well they did, and remember past tasks to do better next time. They can work on their own without people checking every step.
One example is the AI platform made by Mandolin. The company was started by engineers and doctors who had personal experiences with delays in getting specialty drugs. Mandolin’s AI agents act like virtual workers to handle the whole specialty drug approval process. These AI agents are now used in more than 700 clinics across the U.S., helping over 250,000 new patients each year.
The AI agents do these jobs:
This process can cut down work that usually takes days or weeks to just a few hours. Clinics using AI agents see more income and less manual work, thanks to fewer mistakes and faster approvals.
One big change from multi-agent AI is faster patient access to treatments. Instead of waiting weeks for forms to be filled out and approved, patients can start their medicine much sooner—sometimes weeks earlier.
For illnesses like cancer or Alzheimer’s disease, starting treatment early can save lives and improve quality of life. Faster approvals also reduce stress for patients and their caregivers because they don’t have to deal with complicated paperwork for as long.
By automating complicated but routine administrative jobs, multi-agent AI lets healthcare teams spend more time caring for patients and less time on paperwork.
Using AI to automate workflows in healthcare, especially for specialty drug approvals, needs more than just putting in new technology. Healthcare managers must think about linking AI with current systems, how staff will adjust, and following rules and laws.
Key parts of AI workflow automation are:
This makes AI agents different from normal software that just follows set rules or helps with manual work.
It is also important that AI works well with electronic health records, practice management software, and pharmacy systems. IT managers must make sure these systems connect smoothly and protect patient privacy under HIPAA laws.
Doctors and staff accepting the AI is also very important. AI should help them, not replace them. Staff training, clear information about how AI works, and transparent reports on AI tasks help build trust.
Healthcare administrators and IT leaders who want to use multi-agent AI must plan carefully. Here are some points to think about:
Practices using AI to automate specialty approvals report better efficiency and happier patients. These tools help healthcare providers as specialty drugs and patient numbers grow.
Multi-agent AI could help with more than just specialty drug approvals in the future. Research shows new ideas for AI in healthcare like:
Experts talk about an “AI Agent Hospital,” where many AI units work together to manage large healthcare workflows, cut down paperwork, and improve patient care throughout their treatment.
However, some challenges remain. These include connecting AI with current systems, getting doctors and staff to accept it, following laws, and dealing with privacy and fairness. Success depends not just on technology but on healthcare teams using AI responsibly and clearly.
Multi-agent AI is a growing tool for medical administrators, owners, and IT managers in the U.S. It helps by automating steps in specialty drug approval, cutting treatment delays and reducing paperwork, which benefits both providers and patients.
Mandolin’s AI agents aim to close the time-to-access for specialty therapies treating conditions like cancer and Alzheimer’s by automating and speeding up approval workflows, thus helping patients get access to expensive and complex specialty pharmaceuticals faster.
They act as full-time employee equivalents by reading, reasoning, and completing tasks such as benefits verification, prior authorization, and billing across multiple systems, working 24/7 to efficiently handle administrative workflows.
Specialty drugs are costly, take weeks or months for approval, involve complex workflows, and constitute over half of U.S. prescription spend and 75% of the FDA drug pipeline, overwhelming existing healthcare systems.
Healthcare providers report reducing administrative tasks from days to hours, increasing revenue, lowering manual labor overhead, and getting patients on therapy weeks earlier than traditional processes.
Will Yin and Rohit Rustagi, both with medical backgrounds and personal experiences with family members struggling with specialty drug access, founded Mandolin to solve systemic bottlenecks in healthcare delivery.
Unlike traditional tools, Mandolin’s AI agents operate autonomously as a scalable, 24/7 virtual workforce with higher accuracy, performing multi-step, complex workflows end-to-end rather than just supporting human tasks.
Mandolin’s AI agents are live at over 700 clinics nationwide, serving more than 250,000 new patients annually, including large infusion providers and specialty pharmacies.
Multi-agent AI enables automation of complex, multi-step healthcare workflows end-to-end, allowing Mandolin’s agents to collaborate and execute tasks comprehensively without manual intervention.
By automating administrative steps traditionally done manually, Mandolin accelerates access to specialty therapies, enabling patients to start treatments weeks earlier than before.
They recognized that scientific advances were not enough without system-level improvements; the real bottleneck was inefficient processes, which AI technology like Mandolin’s platform could effectively address.